AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
Initial fungicidally active compounds already discovered REHOVOT, Israel, Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing...
Month: February 2025
Vitalchat Secures Series A Funding Led by GHC Industries to Scale Virtual Nursing and Telehealth Solutions
RALEIGH, N.C., Feb. 13, 2025 /PRNewswire/ -- Vitalchat, an innovator of AI-powered ambient solutions for in-patient virtual nursing and procedural telehealth,...
Precision Cardiovascular Appoints Matthew I. Mace to Board of Directors, Bolstering Clinical and Regulatory Leadership
LONDON, Feb. 13, 2025 /PRNewswire/ -- Precision Cardiovascular (PCV), an innovator in next-generation cardiac health solutions, today announced the appointment...
Otolith Labs Announces Data Demonstrating Otolith Technology Effectiveness on Cybersickness from Virtual Reality in Exploratory Study
Original research article published by Frontiers, a top peer-reviewed scientific journal WASHINGTON, Feb. 13, 2025 /PRNewswire/ -- Otolith Labs, a...
Nabla Expands AI Offering with Dictation to Further Streamline Clinical Workflows
Nabla's co-development approach with clinicians informs and drives advances to existing dictation capabilities Voice-to-text Nabla Dictation works together with the...
Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic
Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD,...
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR...
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia...
Restart Life Announces Key Business Updates
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Restart Life Science Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD)...
Beyond Medical Technologies Announces Debt Repayment, Board Addition, and Appointment of Interim CFO
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF)...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are...
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint...
Teleflex Announces Fourth Quarter 2024 Earnings Conference Call Information
WAYNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth...
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 –...
Vistin Pharma ASA: Key information relating to the proposed cash dividend
The Board of Directors of Vistin Pharma ASA (VISTN) will propose to distribute a cash dividend of total NOK 1.25...
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)...
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Cytovation Appoints Martin Dewhurst to its Board of Directors
Brings over 30 years of life sciences industry experienceCo-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025...
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with...
Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results
Oslo, Norway, 13th of February 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and...